| 摘要 |
The disclosure relates to the use of deuterated pirfenidone (compound (I), wherein at least one of R1 – R11 is deuterium), wherein the d-pirfenidone is administered orally between 30 minutes prior to and 2 hours after consuming food. The deuterated pirfenidone may be d3-pirfenidone and the administration with food is to reduce the incidence of gastrointestinal upset, nausea, fatigue, somnolence, dizziness, headache and photosensitivity rash and to reduce the mean maximum plasma concentration. |
